AlzChem Group（0ACT）株式概要アルツケムグループAGは、その子会社とともに、ドイツ、欧州連合、その他の欧州諸国、アジア、NAFTA地域、および国際的に、さまざまな化学特殊製品を開発、生産、販売している。 詳細0ACT ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長4/6過去の実績4/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より54%で取引されている 収益は年間19.07%増加すると予測されています 過去1年間で収益は18.3%増加しました リスク分析高いレベルの非現金収入 すべてのリスクチェックを見る0ACT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€165.3916.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0988m2016201920222025202620282031Revenue €987.7mEarnings €113.6mAdvancedSet Fair ValueView all narrativesAlzChem Group AG 競合他社ElementisSymbol: LSE:ELMMarket cap: UK£863.5mCroda InternationalSymbol: LSE:CRDAMarket cap: UK£4.2bTreattSymbol: LSE:TETMarket cap: UK£177.7mIofinaSymbol: AIM:IOFMarket cap: UK£92.1m価格と性能株価の高値、安値、推移の概要AlzChem Group過去の株価現在の株価€165.3952週高値€189.9052週安値€121.00ベータ0.371ヶ月の変化-4.68%3ヶ月変化5.07%1年変化31.26%3年間の変化722.73%5年間の変化566.88%IPOからの変化705.50%最新ニュースReported Earnings • May 05First quarter 2026 earnings released: EPS: €1.77 (vs €1.44 in 1Q 2025)First quarter 2026 results: EPS: €1.77 (up from €1.44 in 1Q 2025). Revenue: €156.0m (up 6.3% from 1Q 2025). Net income: €18.0m (up 23% from 1Q 2025). Profit margin: 12% (up from 9.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Apr 29Upcoming dividend of €2.10 per shareEligible shareholders must have bought the stock before 06 May 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%).お知らせ • Mar 25AlzChem Group AG, Annual General Meeting, May 05, 2026AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time.Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €175. The fair value is estimated to be €145, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.Declared Dividend • Mar 02Dividend increased to €2.10Dividend of €2.10 is 17% higher than last year. Ex-date: 6th May 2026 Payment date: 8th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 46%.Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €6.28 (vs €5.32 in FY 2024)Full year 2025 results: EPS: €6.28 (up from €5.32 in FY 2024). Revenue: €585.5m (up 3.9% from FY 2024). Net income: €63.5m (up 17% from FY 2024). Profit margin: 11% (up from 9.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.最新情報をもっと見るRecent updatesReported Earnings • May 05First quarter 2026 earnings released: EPS: €1.77 (vs €1.44 in 1Q 2025)First quarter 2026 results: EPS: €1.77 (up from €1.44 in 1Q 2025). Revenue: €156.0m (up 6.3% from 1Q 2025). Net income: €18.0m (up 23% from 1Q 2025). Profit margin: 12% (up from 9.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Apr 29Upcoming dividend of €2.10 per shareEligible shareholders must have bought the stock before 06 May 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%).お知らせ • Mar 25AlzChem Group AG, Annual General Meeting, May 05, 2026AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time.Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €175. The fair value is estimated to be €145, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.Declared Dividend • Mar 02Dividend increased to €2.10Dividend of €2.10 is 17% higher than last year. Ex-date: 6th May 2026 Payment date: 8th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 46%.Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €6.28 (vs €5.32 in FY 2024)Full year 2025 results: EPS: €6.28 (up from €5.32 in FY 2024). Revenue: €585.5m (up 3.9% from FY 2024). Net income: €63.5m (up 17% from FY 2024). Profit margin: 11% (up from 9.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 28AlzChem Group AG announces Annual dividend, payable on May 08, 2026AlzChem Group AG announced Annual dividend of EUR 2.1000 per share payable on May 08, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €157, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 911% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share.お知らせ • Nov 06+ 3 more updatesAlzChem Group AG to Report Q3, 2026 Results on Oct 30, 2026AlzChem Group AG announced that they will report Q3, 2026 results on Oct 30, 2026Buy Or Sell Opportunity • Nov 03Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €157. The fair value is estimated to be €200, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.Reported Earnings • Nov 01Third quarter 2025 earnings released: EPS: €1.61 (vs €1.22 in 3Q 2024)Third quarter 2025 results: EPS: €1.61 (up from €1.22 in 3Q 2024). Revenue: €141.1m (up 6.3% from 3Q 2024). Net income: €16.3m (up 32% from 3Q 2024). Profit margin: 12% (up from 9.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 114% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 24AlzChem Group AG to Report Q3, 2025 Results on Oct 30, 2025AlzChem Group AG announced that they will report Q3, 2025 results on Oct 30, 2025Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: €1.57 (vs €1.41 in 2Q 2024)Second quarter 2025 results: EPS: €1.57 (up from €1.41 in 2Q 2024). Revenue: €147.9m (up 4.2% from 2Q 2024). Net income: €15.8m (up 10% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.Buy Or Sell Opportunity • Jul 31Now 33% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €151. The fair value is estimated to be €114, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €134, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 164% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.Buy Or Sell Opportunity • Jun 26Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to €137. The fair value is estimated to be €112, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Buy Or Sell Opportunity • Jun 05Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 51% to €134. The fair value is estimated to be €111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.お知らせ • May 09AlzChem Group AG to Report First Half, 2025 Results on Jul 30, 2025AlzChem Group AG announced that they will report first half, 2025 results on Jul 30, 2025Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €125, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 9x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 541% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.お知らせ • May 02AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year.Reported Earnings • May 02First quarter 2025 earnings released: EPS: €1.44 (vs €1.20 in 1Q 2024)First quarter 2025 results: EPS: €1.44 (up from €1.20 in 1Q 2024). Revenue: €149.9m (down 1.1% from 1Q 2024). Net income: €14.6m (up 20% from 1Q 2024). Profit margin: 9.7% (up from 8.0% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • May 02Upcoming dividend of €1.80 per shareEligible shareholders must have bought the stock before 09 May 2025. Payment date: 13 May 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (4.6%).Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €103, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 428% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €197 per share.お知らせ • Mar 29AlzChem Group AG, Annual General Meeting, May 08, 2025AlzChem Group AG, Annual General Meeting, May 08, 2025, at 10:00 W. Europe Standard Time.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €88.46, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 343% over the past three years.New Risk • Mar 04New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change).Declared Dividend • Mar 03Dividend increased to €1.80Dividend of €1.80 is 50% higher than last year. Ex-date: 9th May 2025 Payment date: 13th May 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 02Full year 2024 earnings released: EPS: €5.31 (vs €3.40 in FY 2023)Full year 2024 results: EPS: €5.31 (up from €3.40 in FY 2023). Revenue: €571.5m (up 4.7% from FY 2023). Net income: €54.1m (up 56% from FY 2023). Profit margin: 9.5% (up from 6.3% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Dec 06Alzchem Group Ag Appoints Martina Spitzer as A New Member of the Management Board, Effective from January 1, 2025AlzChem Group AG approved the appointment of Martina Spitzer as a new member of the Management Board for a term of three years from January 1, 2025 to December 31, 2027. In her new position as Chief Sales Officer (CSO), she will be responsible for the areas of Health & Nutrition (Creapure®), Fine Chemicals (Chemicals & Applications) and Sustainability (ESG). Ms. Spitzer’s appointment as CSO represents the next important step in the early succession planning for the Management Board. Ms. Spitzer is now already taking over two important business areas in sales, as Dr. Weichselbaumer will be in charge of the future project of setting up production in the USA. Ms. Spitzer has been with the Alzchem Group since 1999. In 2020, she was appointed Head of Alzchem’s entire chemical sales division, before she shifted her focus to strategic corporate development and ESG in 2022 after around 15 years in sales. In this role, she was instrumental in the introduction of the sustainability division, the optimization of central business processes and the implementation of forward-looking projects.お知らせ • Nov 27AlzChem Group AG to Report Q1, 2025 Results on Apr 30, 2025AlzChem Group AG announced that they will report Q1, 2025 results on Apr 30, 2025Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: €1.22 (vs €0.85 in 3Q 2023)Third quarter 2024 results: EPS: €1.22 (up from €0.85 in 3Q 2023). Revenue: €132.7m (up 7.0% from 3Q 2023). Net income: €12.4m (up 44% from 3Q 2023). Profit margin: 9.3% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Nov 08AlzChem Group AG to Report Fiscal Year 2024 Results on Feb 28, 2025AlzChem Group AG announced that they will report fiscal year 2024 results on Feb 28, 2025Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €51.80, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.39 per share.Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: €0.71 (vs €0.70 in 2Q 2023)Second quarter 2024 results: EPS: €0.71 (up from €0.70 in 2Q 2023). Revenue: €139.9m (up 5.2% from 2Q 2023). Net income: €14.4m (up 100% from 2Q 2023). Profit margin: 10% (up from 5.4% in 2Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Aug 02AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024AlzChem Group AG announced that they will report Q3, 2024 results on Nov 07, 2024お知らせ • May 09AlzChem Group AG to Report First Half, 2024 Results on Aug 01, 2024AlzChem Group AG announced that they will report first half, 2024 results on Aug 01, 2024Reported Earnings • May 01First quarter 2024 earnings released: EPS: €1.20 (vs €0.76 in 1Q 2023)First quarter 2024 results: EPS: €1.20 (up from €0.76 in 1Q 2023). Revenue: €153.6m (up 1.4% from 1Q 2023). Net income: €12.2m (up 59% from 1Q 2023). Profit margin: 7.9% (up from 5.1% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.Declared Dividend • Mar 28Dividend increased to €1.20Dividend of €1.20 is 14% higher than last year. Ex-date: 8th May 2024 Payment date: 10th May 2024 Dividend yield will be 3.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 1.5% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 05Full year 2023 earnings released: EPS: €3.40 (vs €2.97 in FY 2022)Full year 2023 results: EPS: €3.40 (up from €2.97 in FY 2022). Revenue: €554.5m (flat on FY 2022). Net income: €34.6m (up 15% from FY 2022). Profit margin: 6.2% (up from 5.5% in FY 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 30AlzChem Group AG to Report Q1, 2024 Results on Apr 30, 2024AlzChem Group AG announced that they will report Q1, 2024 results on Apr 30, 2024お知らせ • Oct 27AlzChem Group AG to Report Fiscal Year 2023 Results on Mar 01, 2024AlzChem Group AG announced that they will report fiscal year 2023 results on Mar 01, 2024お知らせ • Sep 19AlzChem Group AG to Report Q3, 2023 Results on Oct 26, 2023AlzChem Group AG announced that they will report Q3, 2023 results on Oct 26, 2023New Risk • Aug 05New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 44% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (44% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Aug 04Second quarter 2023 earnings released: EPS: €0.71 (vs €0.95 in 2Q 2022)Second quarter 2023 results: EPS: €0.71 (down from €0.95 in 2Q 2022). Revenue: €128.5m (down 14% from 2Q 2022). Net income: €7.20m (down 25% from 2Q 2022). Profit margin: 5.6% (down from 6.5% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • May 05AlzChem Group AG to Report First Half, 2023 Results on Aug 03, 2023AlzChem Group AG announced that they will report first half, 2023 results on Aug 03, 2023Reported Earnings • May 05First quarter 2023 earnings released: EPS: €0.76 (vs €0.76 in 1Q 2022)First quarter 2023 results: EPS: €0.76 (down from €0.76 in 1Q 2022). Revenue: €156.0m (up 19% from 1Q 2022). Net income: €7.67m (flat on 1Q 2022). Profit margin: 4.9% (down from 5.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €2.96 (vs €2.72 in FY 2021)Full year 2022 results: EPS: €2.96 (up from €2.72 in FY 2021). Revenue: €566.4m (up 32% from FY 2021). Net income: €30.1m (up 8.9% from FY 2021). Profit margin: 5.3% (down from 6.4% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Dec 09AlzChem Group AG, Annual General Meeting, May 11, 2023AlzChem Group AG, Annual General Meeting, May 11, 2023, at 10:00 Central European Standard Time.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: €0.59 (vs €0.46 in 3Q 2021)Third quarter 2022 results: EPS: €0.59 (up from €0.46 in 3Q 2021). Revenue: €145.1m (up 48% from 3Q 2021). Net income: €5.93m (up 27% from 3Q 2021). Profit margin: 4.1% (down from 4.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Oct 27AlzChem Group AG to Report Fiscal Year 2022 Final Results on Feb 28, 2023AlzChem Group AG announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Feb 28, 2023Reported Earnings • May 12First quarter 2022 earnings released: EPS: €0.76 (vs €0.78 in 1Q 2021)First quarter 2022 results: EPS: €0.76 (down from €0.78 in 1Q 2021). Revenue: €133.5m (up 23% from 1Q 2021). Net income: €7.70m (down 2.4% from 1Q 2021). Profit margin: 5.8% (down from 7.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11% compared to a 18% decline forecast for the industry in the United Kingdom.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €0.46 (vs €0.37 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €98.1m (up 17% from 3Q 2020). Net income: €4.69m (up 25% from 3Q 2020). Profit margin: 4.8% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • May 07First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €108.3m (up 13% from 1Q 2020). Net income: €7.89m (up 80% from 1Q 2020). Profit margin: 7.3% (up from 4.6% in 1Q 2020). The increase in margin was driven by higher revenue.Upcoming Dividend • May 07Upcoming dividend of €0.77 per shareEligible shareholders must have bought the stock before 13 May 2021. Payment date: 18 May 2021. Trailing yield: 3.1%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.6%).株主還元0ACTGB ChemicalsGB 市場7D0.5%5.5%1.5%1Y31.3%8.7%19.4%株主還元を見る業界別リターン: 0ACT過去 1 年間で8.7 % の収益を上げたUK Chemicals業界を上回りました。リターン対市場: 0ACT過去 1 年間で19.4 % の収益を上げたUK市場を上回りました。価格変動Is 0ACT's price volatile compared to industry and market?0ACT volatility0ACT Average Weekly Movement6.2%Chemicals Industry Average Movement8.0%Market Average Movement5.7%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.1%安定した株価: 0ACT 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 0ACTの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19081,680Andreas Niedermaierwww.alzchem.comアルツケムグループAGは、その子会社とともに、ドイツ、欧州連合、欧州以外の地域、アジア、NAFTA地域、および国際的に、さまざまな化学特殊製品の開発、生産、販売を行っている。同社は3つのセグメントで事業を展開している：特殊化学品事業、基礎・中間体事業、その他・持株事業である。特殊化学品部門は、化学、食品、飼料、防衛技術、再生可能エネルギー産業で使用される特殊化学品を販売している。このセグメントでは、複合材料や接着剤、セラミック用窒化ケイ素、太陽電池モジュールなどを製造している。基礎・中間体部門は、特殊化学品原料、農業・冶金用製品、石灰、炭素、電力から製造される化学工業用中間体を生産している。また、農薬・医薬原体原料としてのグアニジン塩の製造・販売も行っている。その他・持株事業では、ケミカルパークの運営・管理サービス、各種インフラサービスの製造・販売を行っている。農業分野では「CALCIUM CYANAMIDE PERLKA」、「EMINEX」、「DORMEX」、「ALZOGUR」、「SITOFEX」、「BREAK-THRU」ブランド、動物栄養分野では「CREAMINO」ブランド、人間栄養分野では「CREAPURE」、「CREAVITALIS」、「LIVADUR」、「ALIPURE」ブランド、医薬品分野では「GUANIDINE SALTS - BIOSELECT」ブランドで製品とサービスを提供している；GUANIDINSALZE -BIOSELECT」、「CYANAMIDE」、「DICYANDIAMIDE」、「GUANAMINE」、「NITRILES」、「MELFLOCK」、「ALZOFIX」、「THIOUREA」、「NITROGUANIDINE」ブランドのファインケミカル部門、「CAD」、「CALCIPRO」、「CALZOT」ブランドの冶金部門、「テクニカルガス」、「炭化カルシウム」、「DYHARD」、「SILZOT」ブランドの再生可能エネルギー部門、および受託微粉化や製造などのカスタム合成部門。AlzChem Group AGは1908年に設立され、ドイツのトロストベルグに本社を置いている。もっと見るAlzChem Group AG 基礎のまとめAlzChem Group の収益と売上を時価総額と比較するとどうか。0ACT 基礎統計学時価総額€1.68b収益（TTM）€66.82m売上高(TTM)€581.10m25.1xPER（株価収益率2.9xP/Sレシオ0ACT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0ACT 損益計算書（TTM）収益€581.10m売上原価€195.25m売上総利益€385.85mその他の費用€319.03m収益€66.82m直近の収益報告Mar 31, 2026次回決算日Jul 30, 2026一株当たり利益（EPS）6.60グロス・マージン66.40%純利益率11.50%有利子負債／自己資本比率14.3%0ACT の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.3%現在の配当利回り33%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 11:02終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AlzChem Group AG 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Konstantin WiechertBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchGerhard OrgonasBerenberg5 その他のアナリストを表示
Reported Earnings • May 05First quarter 2026 earnings released: EPS: €1.77 (vs €1.44 in 1Q 2025)First quarter 2026 results: EPS: €1.77 (up from €1.44 in 1Q 2025). Revenue: €156.0m (up 6.3% from 1Q 2025). Net income: €18.0m (up 23% from 1Q 2025). Profit margin: 12% (up from 9.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Apr 29Upcoming dividend of €2.10 per shareEligible shareholders must have bought the stock before 06 May 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%).
お知らせ • Mar 25AlzChem Group AG, Annual General Meeting, May 05, 2026AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time.
Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €175. The fair value is estimated to be €145, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.
Declared Dividend • Mar 02Dividend increased to €2.10Dividend of €2.10 is 17% higher than last year. Ex-date: 6th May 2026 Payment date: 8th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 46%.
Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €6.28 (vs €5.32 in FY 2024)Full year 2025 results: EPS: €6.28 (up from €5.32 in FY 2024). Revenue: €585.5m (up 3.9% from FY 2024). Net income: €63.5m (up 17% from FY 2024). Profit margin: 11% (up from 9.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 05First quarter 2026 earnings released: EPS: €1.77 (vs €1.44 in 1Q 2025)First quarter 2026 results: EPS: €1.77 (up from €1.44 in 1Q 2025). Revenue: €156.0m (up 6.3% from 1Q 2025). Net income: €18.0m (up 23% from 1Q 2025). Profit margin: 12% (up from 9.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Apr 29Upcoming dividend of €2.10 per shareEligible shareholders must have bought the stock before 06 May 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%).
お知らせ • Mar 25AlzChem Group AG, Annual General Meeting, May 05, 2026AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time.
Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €175. The fair value is estimated to be €145, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.
Declared Dividend • Mar 02Dividend increased to €2.10Dividend of €2.10 is 17% higher than last year. Ex-date: 6th May 2026 Payment date: 8th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 46%.
Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €6.28 (vs €5.32 in FY 2024)Full year 2025 results: EPS: €6.28 (up from €5.32 in FY 2024). Revenue: €585.5m (up 3.9% from FY 2024). Net income: €63.5m (up 17% from FY 2024). Profit margin: 11% (up from 9.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 28AlzChem Group AG announces Annual dividend, payable on May 08, 2026AlzChem Group AG announced Annual dividend of EUR 2.1000 per share payable on May 08, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €157, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 911% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share.
お知らせ • Nov 06+ 3 more updatesAlzChem Group AG to Report Q3, 2026 Results on Oct 30, 2026AlzChem Group AG announced that they will report Q3, 2026 results on Oct 30, 2026
Buy Or Sell Opportunity • Nov 03Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €157. The fair value is estimated to be €200, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
Reported Earnings • Nov 01Third quarter 2025 earnings released: EPS: €1.61 (vs €1.22 in 3Q 2024)Third quarter 2025 results: EPS: €1.61 (up from €1.22 in 3Q 2024). Revenue: €141.1m (up 6.3% from 3Q 2024). Net income: €16.3m (up 32% from 3Q 2024). Profit margin: 12% (up from 9.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 114% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 24AlzChem Group AG to Report Q3, 2025 Results on Oct 30, 2025AlzChem Group AG announced that they will report Q3, 2025 results on Oct 30, 2025
Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: €1.57 (vs €1.41 in 2Q 2024)Second quarter 2025 results: EPS: €1.57 (up from €1.41 in 2Q 2024). Revenue: €147.9m (up 4.2% from 2Q 2024). Net income: €15.8m (up 10% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
Buy Or Sell Opportunity • Jul 31Now 33% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €151. The fair value is estimated to be €114, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €134, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 164% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.
Buy Or Sell Opportunity • Jun 26Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to €137. The fair value is estimated to be €112, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Buy Or Sell Opportunity • Jun 05Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 51% to €134. The fair value is estimated to be €111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
お知らせ • May 09AlzChem Group AG to Report First Half, 2025 Results on Jul 30, 2025AlzChem Group AG announced that they will report first half, 2025 results on Jul 30, 2025
Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €125, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 9x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 541% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.
お知らせ • May 02AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year.
Reported Earnings • May 02First quarter 2025 earnings released: EPS: €1.44 (vs €1.20 in 1Q 2024)First quarter 2025 results: EPS: €1.44 (up from €1.20 in 1Q 2024). Revenue: €149.9m (down 1.1% from 1Q 2024). Net income: €14.6m (up 20% from 1Q 2024). Profit margin: 9.7% (up from 8.0% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • May 02Upcoming dividend of €1.80 per shareEligible shareholders must have bought the stock before 09 May 2025. Payment date: 13 May 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (4.6%).
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €103, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 428% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €197 per share.
お知らせ • Mar 29AlzChem Group AG, Annual General Meeting, May 08, 2025AlzChem Group AG, Annual General Meeting, May 08, 2025, at 10:00 W. Europe Standard Time.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €88.46, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 343% over the past three years.
New Risk • Mar 04New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change).
Declared Dividend • Mar 03Dividend increased to €1.80Dividend of €1.80 is 50% higher than last year. Ex-date: 9th May 2025 Payment date: 13th May 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 02Full year 2024 earnings released: EPS: €5.31 (vs €3.40 in FY 2023)Full year 2024 results: EPS: €5.31 (up from €3.40 in FY 2023). Revenue: €571.5m (up 4.7% from FY 2023). Net income: €54.1m (up 56% from FY 2023). Profit margin: 9.5% (up from 6.3% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Dec 06Alzchem Group Ag Appoints Martina Spitzer as A New Member of the Management Board, Effective from January 1, 2025AlzChem Group AG approved the appointment of Martina Spitzer as a new member of the Management Board for a term of three years from January 1, 2025 to December 31, 2027. In her new position as Chief Sales Officer (CSO), she will be responsible for the areas of Health & Nutrition (Creapure®), Fine Chemicals (Chemicals & Applications) and Sustainability (ESG). Ms. Spitzer’s appointment as CSO represents the next important step in the early succession planning for the Management Board. Ms. Spitzer is now already taking over two important business areas in sales, as Dr. Weichselbaumer will be in charge of the future project of setting up production in the USA. Ms. Spitzer has been with the Alzchem Group since 1999. In 2020, she was appointed Head of Alzchem’s entire chemical sales division, before she shifted her focus to strategic corporate development and ESG in 2022 after around 15 years in sales. In this role, she was instrumental in the introduction of the sustainability division, the optimization of central business processes and the implementation of forward-looking projects.
お知らせ • Nov 27AlzChem Group AG to Report Q1, 2025 Results on Apr 30, 2025AlzChem Group AG announced that they will report Q1, 2025 results on Apr 30, 2025
Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: €1.22 (vs €0.85 in 3Q 2023)Third quarter 2024 results: EPS: €1.22 (up from €0.85 in 3Q 2023). Revenue: €132.7m (up 7.0% from 3Q 2023). Net income: €12.4m (up 44% from 3Q 2023). Profit margin: 9.3% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Nov 08AlzChem Group AG to Report Fiscal Year 2024 Results on Feb 28, 2025AlzChem Group AG announced that they will report fiscal year 2024 results on Feb 28, 2025
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €51.80, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.39 per share.
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: €0.71 (vs €0.70 in 2Q 2023)Second quarter 2024 results: EPS: €0.71 (up from €0.70 in 2Q 2023). Revenue: €139.9m (up 5.2% from 2Q 2023). Net income: €14.4m (up 100% from 2Q 2023). Profit margin: 10% (up from 5.4% in 2Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Aug 02AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024AlzChem Group AG announced that they will report Q3, 2024 results on Nov 07, 2024
お知らせ • May 09AlzChem Group AG to Report First Half, 2024 Results on Aug 01, 2024AlzChem Group AG announced that they will report first half, 2024 results on Aug 01, 2024
Reported Earnings • May 01First quarter 2024 earnings released: EPS: €1.20 (vs €0.76 in 1Q 2023)First quarter 2024 results: EPS: €1.20 (up from €0.76 in 1Q 2023). Revenue: €153.6m (up 1.4% from 1Q 2023). Net income: €12.2m (up 59% from 1Q 2023). Profit margin: 7.9% (up from 5.1% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.
Declared Dividend • Mar 28Dividend increased to €1.20Dividend of €1.20 is 14% higher than last year. Ex-date: 8th May 2024 Payment date: 10th May 2024 Dividend yield will be 3.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 1.5% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 05Full year 2023 earnings released: EPS: €3.40 (vs €2.97 in FY 2022)Full year 2023 results: EPS: €3.40 (up from €2.97 in FY 2022). Revenue: €554.5m (flat on FY 2022). Net income: €34.6m (up 15% from FY 2022). Profit margin: 6.2% (up from 5.5% in FY 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 30AlzChem Group AG to Report Q1, 2024 Results on Apr 30, 2024AlzChem Group AG announced that they will report Q1, 2024 results on Apr 30, 2024
お知らせ • Oct 27AlzChem Group AG to Report Fiscal Year 2023 Results on Mar 01, 2024AlzChem Group AG announced that they will report fiscal year 2023 results on Mar 01, 2024
お知らせ • Sep 19AlzChem Group AG to Report Q3, 2023 Results on Oct 26, 2023AlzChem Group AG announced that they will report Q3, 2023 results on Oct 26, 2023
New Risk • Aug 05New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 44% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (44% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Aug 04Second quarter 2023 earnings released: EPS: €0.71 (vs €0.95 in 2Q 2022)Second quarter 2023 results: EPS: €0.71 (down from €0.95 in 2Q 2022). Revenue: €128.5m (down 14% from 2Q 2022). Net income: €7.20m (down 25% from 2Q 2022). Profit margin: 5.6% (down from 6.5% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • May 05AlzChem Group AG to Report First Half, 2023 Results on Aug 03, 2023AlzChem Group AG announced that they will report first half, 2023 results on Aug 03, 2023
Reported Earnings • May 05First quarter 2023 earnings released: EPS: €0.76 (vs €0.76 in 1Q 2022)First quarter 2023 results: EPS: €0.76 (down from €0.76 in 1Q 2022). Revenue: €156.0m (up 19% from 1Q 2022). Net income: €7.67m (flat on 1Q 2022). Profit margin: 4.9% (down from 5.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €2.96 (vs €2.72 in FY 2021)Full year 2022 results: EPS: €2.96 (up from €2.72 in FY 2021). Revenue: €566.4m (up 32% from FY 2021). Net income: €30.1m (up 8.9% from FY 2021). Profit margin: 5.3% (down from 6.4% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Dec 09AlzChem Group AG, Annual General Meeting, May 11, 2023AlzChem Group AG, Annual General Meeting, May 11, 2023, at 10:00 Central European Standard Time.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: €0.59 (vs €0.46 in 3Q 2021)Third quarter 2022 results: EPS: €0.59 (up from €0.46 in 3Q 2021). Revenue: €145.1m (up 48% from 3Q 2021). Net income: €5.93m (up 27% from 3Q 2021). Profit margin: 4.1% (down from 4.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Oct 27AlzChem Group AG to Report Fiscal Year 2022 Final Results on Feb 28, 2023AlzChem Group AG announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Feb 28, 2023
Reported Earnings • May 12First quarter 2022 earnings released: EPS: €0.76 (vs €0.78 in 1Q 2021)First quarter 2022 results: EPS: €0.76 (down from €0.78 in 1Q 2021). Revenue: €133.5m (up 23% from 1Q 2021). Net income: €7.70m (down 2.4% from 1Q 2021). Profit margin: 5.8% (down from 7.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11% compared to a 18% decline forecast for the industry in the United Kingdom.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €0.46 (vs €0.37 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €98.1m (up 17% from 3Q 2020). Net income: €4.69m (up 25% from 3Q 2020). Profit margin: 4.8% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • May 07First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €108.3m (up 13% from 1Q 2020). Net income: €7.89m (up 80% from 1Q 2020). Profit margin: 7.3% (up from 4.6% in 1Q 2020). The increase in margin was driven by higher revenue.
Upcoming Dividend • May 07Upcoming dividend of €0.77 per shareEligible shareholders must have bought the stock before 13 May 2021. Payment date: 18 May 2021. Trailing yield: 3.1%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.6%).
